Pancreatic Cancer and Thyroid Cancer Risks with Dulaglutide Treatment

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/45173
• EU PAS number:
  EUPAS45172
• Study ID:
  45173
• Official title and acronym:
  Pancreatic Cancer and Thyroid Cancer Risks with Dulaglutide Treatment
• DARWIN EU® study:
  No
• Study countries:
  Finland

  Sweden

  United Kingdom

  United States
• Study description:
  A non-interventional study aims to evaluate the association of dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist, with pancreatic cancer and thyroid cancer, including medullary thyroid carcinoma. Adults with type 2 diabetes who initiated dulaglutide will be compared to those who initiated other second-line anti-hyperglycemic drugs.
• Study status:
  Planned

Research institution and networks

Institutions

IQVIA

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 26/01/2018

Actual: 31/01/2018

Study start date

Planned: 31/01/2022

Data analysis start date

Planned: 31/01/2023

Date of interim report, if expected

Planned: 31/12/2024

Date of final study report

Planned: 31/12/2030

Sources of funding

EU institutional research programme

Other

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)